You are here:
Direct Healthcare Professional Communication (DHPC) on leuprorelin-containing depot drugs: need to strictly follow the instructions regarding preparation and administration to reduce the risk of application errors
2020.07.30
Active substance: leuprorelin
The marketing authorization holders of leuprorelin containing medicines, in coordination with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), would like to inform that handling errors have been reported with leuprorelin-containing depot medicinal products, potentially resulting in lack of efficacy. Leuprorelin-containing depot products should be prepared, reconstituted and administered only by healthcare professionals who are familiar with these procedures.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN